Skip to main
MPLT

MPLT Stock Forecast & Price Target

MPLT Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 71%
Buy 29%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

MapLight Therapeutics is a biopharmaceutical company with a promising drug in development for schizophrenia and Alzheimer's disease psychosis. Their focus on safety and efficacy, as well as the potential for success in other neuropsychiatric disorders, presents opportunities for growth. However, competition and pipeline risks should be considered. Ongoing clinical trials will be key in determining the success and market impact of their drug.

Bears say

MapLight Therapeutics is facing a challenging market with a highly competitive landscape and a long period of drug development before product commercialization. There is little financial data available for the company besides its impressive discovery platform and promising phase 2 trial results, making it difficult to accurately assess its financial standing and potential for success. Additionally, the success of ML-007C-MA relies heavily on the results of ongoing clinical trials and regulatory approval, which are subject to uncertainty and potential setbacks.

MPLT has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 71% of analysts recommend a Strong Buy, 29% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of MapLight Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About MapLight Therapeutics Inc (MPLT) Forecast

Analysts have given MPLT a Strong Buy based on their latest research and market trends.

According to 7 analysts, MPLT has a Strong Buy consensus rating as of May 12, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $34.43, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $34.43, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

MapLight Therapeutics Inc (MPLT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.